InsidersTradesSigma
Track the Intuitive Surgical INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Intuitive Surgical INC has logged 395 reports. Market capitalisation: €140.2bn. The latest transaction was reported on 21 August 2026 (Cession). Among the most active insiders: Brosius Mark. All data is accessible without an account.
395
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€14m
63 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Intuitive Surgical INC Buy (bullish), based on 30 analysts. Average price target: US$478.01.
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,021 of 29,057 companies
61.0
score / 100
Value34
Quality88
FCF yld1.9%
Earn yld2.1%
EV/EBITDA36.9x
ROE17%
Gross mgn66%
Net mgn28%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2026
Declarations395 total
77 shares@ US$396.37Common StockSEC:0002010300-26-000029:0
77 shares@ US$375.57Common StockSEC:0002010300-26-000029:1
77 shares@ US$390.670.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000027:0
77 shares@ US$394.000.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000027:1
77 shares@ US$394.260.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000027:2
10,000 shares@ US$400.000.0028% mcap9.0% of flowCommon StockSEC:0001280628-26-000014:0
400 shares@ US$379.000.0001% mcap8.6% of flowCommon StockSEC:0001781750-26-000006:0
72 shares@ US$393.100.0000% mcap1.6% of flowCommon StockSEC:0001781750-26-000006:1
28 shares@ US$351.000.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000025:1
28 shares@ US$346.830.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000025:0
28 shares@ US$344.000.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000023:0
28 shares@ US$365.580.0000% mcap0.4% of flowCommon StockSEC:0002010300-26-000023:1
28 shares@ US$360.210.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000023:2
1,910 shares0Common StockSEC:0001519593-26-000012:0
947 shares@ US$411.550.0003% mcap2.4% of flowCommon StockSEC:0001519593-26-000012:1
23 sharesCommon StockSEC:0002010300-26-000021:0
25 sharesCommon StockSEC:0002010300-26-000021:1
23 sharesCommon StockSEC:0002010300-26-000019:1
23 sharesCommon StockSEC:0002010300-26-000019:0
23 sharesCommon StockSEC:0002010300-26-000019:2
18 shares@ US$446.040.0000% mcap0.5% of flowCommon StockSEC:0002010300-26-000017:0
18 shares@ US$439.800.0000% mcap0.5% of flowCommon StockSEC:0002010300-26-000017:1
750 shares0Common StockSEC:0001277620-26-000002:0
531 shares0Common StockSEC:0001249557-26-000002:0
25 of 395 declarations
关于 Intuitive Surgical INC
Intuitive Surgical Inc. 是一家在美国纳斯达克上市的美国领先医疗技术公司。该公司成立于1995年，总部位于加利福尼亚州桑尼维尔，被广泛认为是机器人辅助微创手术的先驱。从投资者的角度来看，ISRG 最好被理解为一个平台业务：它销售机器人系统、器械和配件以及服务，从而创造了可观的经常性收入来源，并在医院和门诊环境中建立了稳定的客户群。([sec.gov](https://www.sec.gov/Archives/edgar/data/1035267/000103526725000099/a2024_intuitiveannualrepor.pdf?utm_source=openai)) 该公司的核心业务是达芬奇（da Vinci）系列手术机器人系统，辅以用于肺活检和其他腔内应用的Ion腔内系统。Intuitive 服务于广泛的手术，包括泌尿外科、妇科、普通外科、胸外科、结直肠外科以及选定的耳鼻喉科应用，具体取决于每个市场的监管批准。一个重要的战略步骤是推出了达芬奇 5，这是该公司最新的平台一代，增加了软件功能和实时手术洞察，旨在提高工作流程效率和系统性能。([intuitive.com](https://www.intuitive.com/en-us?utm_source=openai)) 竞争定位仍然是 Intuitive 的主要优势之一。该公司是全球手术机器人领域的领导者，拥有强大的品牌资产、庞大的装机量、广泛的外科医生熟悉度以及难以被竞争对手迅速复制的培训、临床支持和服务生态系统。这种领导地位在2025年继续转化为健康的手术量增长，管理层更新强调达芬奇和Ion在全球范围内的使用量不断增加，以及达芬奇 5 的采用率不断提高。([isrg.intuitive.com](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-preliminary-fourth-quarter-and-full-year-5?utm_source=openai)) 从地理上看，Intuitive 是一家总部位于美国的公司，业务遍及北美、欧洲和其他发达国际市场。最近的里程碑强化了其创新管线：FDA 在2025年扩大了达芬奇 SP 的适应症，Intuitive 推出了达芬奇 5 的新实时软件功能，增强了 Ion 中的人工智能和成像集成，并获得了达芬奇 5 在欧洲的CE标志批准。对于股票投资者而言，技术领先、经常性收入和微创手术的长期普及相结合，支撑了其长期投资论点。([isrg.intuitive.com](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-fda-clearance-da-vinci-single-port-transanal?utm_source=openai))
